ClinicalTrials.gg
CompletedNCT01639001Updated Dec 8, 2020Results posted

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

A Phase 3 interventional study of Crizotinib and Pemetrexed/Cisplatin in NSCLC (Non-small Cell Lung Cancer), sponsored by Pfizer. Completed at 47 sites in 5 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-12-08.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
207
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 6 under way, 1 of them phase 3. Crizotinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
6th of 23
207 · median 80
Started
2012
the only one that year
Phase 3
4 of 23
none open now
Registered
6th of 23
by date
Lead sponsor
9 of 23
Pfizer

Among the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, this one is the 6th largest by enrollment, is the only one that started in 2012, is one of 4 in phase 3, and was the 6th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

4 of the 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About crizotinib

Crizotinib: first FDA approval 2011 (XALKORI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing crizotinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase III, Randomized, Open-label, Efficacy and Safety Study of Crizotinib single agent versus Chemotherapy Regimens (Pemetrexed/Cisplatin or Pemetrexed/Carboplatin) in First-Line ALK (Anaplastic Lymphoma Kinase) Positive East Asian Non-Small Cell Lung Cancer Patients. The objective of the study is to demonstrate that Crizotinib is superior to first-line chemotherapy pemetrexed/cisplatin or pemetrexed/carboplatin in prolonging Progression Free Survival (PFS) in East Asian patients with advanced Non-Squamous NSCLC whose tumors harbor a translocation or inversion event involving the ALK (Anaplastic Lymphoma Kinase) gene locus.

03

Conditions studied

  • NSCLC (Non-small Cell Lung Cancer)

Keywords

  • Crizotinib
  • ALK positive
  • ALK
  • Anaplastic Lymphoma Kinase
  • NSCLC
  • Non-Small Cell Lung Cancer
  • Frontline
  • 1L
  • Previously Untreated
  • East Asian
  • Non-Squamous
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically proven diagnosis of locally advanced not suitable for local treatment, recurrent and non-squamous cell carcinoma of the lung.
  • Positive for translocation or inversion events involving the ALK gene locus.
  • No prior systemic treatment for locally advanced or metastatic disease. Patients with only if treated and neurologically stable for at least 2 weeks and are not taking any medications in Exclusion Criteria
  • Evidence of a personally signed and dated document and willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures including completion of patient reported outcome [PRO] measures.

Exclusion criteria

Exclusion Criteria:

  • Current treatment on another therapeutic clinical trial.
  • Prior therapy directly targeting ALK.
  • Any of the following within the 3 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including . Appropriate treatment with anticoagulants is permitted.
  • Ongoing cardiac dysrhythmias of Grade >=2, uncontrolled atrial fibrillation of any grade, or >470 msec.
  • Pregnancy or breastfeeding.
  • Use of drugs or foods that are known potent inducers/inhibitors Concurrent use of drugs that are CYP3A substrates with narrow therapeutic indices.
  • Known infection
  • History of extensive disseminated/bilateral or known presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis, but not history of prior radiation pneumonitis.
  • Other severe acute or chronic medical conditions (including severe gastrointestinal conditions such as diarrhea or ulcer) or psychiatric conditions, or end-stage renal disease on hemodialysis, or laboratory abnormalities that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration, and which would, therefore, make the patient inappropriate for entry into this study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
207 participants (actual)

Study arms

  • Experimental
    Crizotinib

    Crizotinib

    Drug: Crizotinib

  • Active comparator
    Chemotherapy

    Chemotherapy \[Option at Investigator's Choice\]

    Drug: Pemetrexed/Cisplatin · Drug: Pemetrexed/Carboplatin

Interventions

  • 250 mg two times daily \[BID\], oral, on a continuous daily dosing schedule. Cycles are defined in 21 day periods.

  • DrugPemetrexed/Cisplatin

    Drug pages: Pemetrexed · Cisplatin

    Option 1: Pemetrexed/Cisplatin; Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Cisplatin, 75 mg/m\^2 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and cisplatin will be repeated every 3 weeks for a maximum of 6 cycles.

  • DrugPemetrexed/Carboplatin

    Drug pages: Pemetrexed · Carboplatin

    Option 2: Pemetrexed/Carboplatin. Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Carboplatin, at a dose calculated to produce an AUC of 5 or 6 mg.min/mL will be administered by infusion according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and carboplatin will be repeated every 3 weeks for a maximum of 6 cycles.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) Based on IRR by Treatment Arm

    PFS was defined as the time from the date of randomization to the date of the first documentation of objective tumor progression (by IRR) or death on study due to any cause, whichever occured first. If tumor progression data included more than 1 date, the first date was used. PFS (in months) was calculated as (first event date - randomization date +1)/30.44. Progression is defined using RECIST v1.1, as at least a 20% increase (including an absolute increase of at least 5 millimeters) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

    Time frame: Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)

Secondary outcomes

  1. Objective Response Rate (ORR) - Percentage of Participants With Objective Response Based on IRR

    Percentage of participants with objective response of complete response (CR) or partial response (PR) according to RECIST version 1.1. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

    Time frame: Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (assessed up to 33 months)

  2. Overall Survival (OS)

    OS was defined as the time from randomization to the date of death due to any cause. OS (in months) was calculated as (date of death - date of randomization +1)/30.44. For participants who were lost to follow-up or withdrew consent, the OS was censored on the last date that participants were known to be alive.

    Time frame: From randomization to death or last date known as alive for those who were lost to follow-up or withdrew consent (assessed up to 64 months).

  3. Percentage of Participants With Disease Control at 12 Weeks Based on IRR

    Disease Control Rate (DCR) at 12 weeks is defined as the percent of participants with CR, PR or stable disease (SD) at 12 weeks according to RECIST version 1.1 as determined by the IRR. The best response of SD can be assigned if SD criteria were met at least once after randomization at a minimum interval of 6 weeks. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

    Time frame: From randomization to Week 12

  4. Estimate of the Percentage of Participants Surviving at 1 Year and at 18 Months

    Probability of survival 1 year and 18 month after randomization. The probability of survival at 1 year was estimated using the Kaplan Meier method and a 2-sided 95% CI for the log \[-log(1-year survival probability)\] was calculated using a normal approximation and then back transformed to give a CI for the 1-year survival probability itself. The probability of survival at 18 months was estimated similarly.

    Time frame: From randomization to 1 year and from randomization to 18 months

  5. Duration of Response (DR) Based on IRR

    DR was defined as the time from the first documentation of objective tumor response (CR or PR), as determined by the IRR, to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used. DR (in weeks) was calculated as (first date of PD or death - first date of CR or PR +1)/7. DR was only calculated for the subgroup of participants with an objective tumor response.

    Time frame: From objective response to date of progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, up to 33 months)

  6. Time to Tumor Response (TTR) Based on IRR

    TTR was defined as the time from randomization to first documentation of objective tumor response (CR or PR) as determined by the IRR. For participants proceeding from PR to CR, the onset of PR was taken as the onset of response. TTR was calculated for the subgroup of participants with objective tumor response.

    Time frame: Randomization to first documentation of objective tumor response (up to 33 months).

  7. Time to Progression (TTP) Based on IRR

    TTP was defined as the time from the date of randomization to the date of the first documentation of objective tumor progression, as determined by IRR. If tumor progression data included more than 1 date, the first date was used. TTP (in months) was calculated as (first event date - randomization date +1)/30.44.

    Time frame: Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, up to 33 months)

  8. Intracranial Time to Progression (IC-TTP) Based on IRR

    IC-TTP was defined similarly to TTP, but only considering intracranial disease (excluding extracranial disease) and the progression was determined based on either new brain metastases or progression of existing brain metastases.

    Time frame: Randomization to objective intracranial progression or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, up to 33 months)

  9. Extracranial Time to Progression (EC-TTP) Based on IRR

    EC-TTP was defined similarly to TTP, but only considering extracranial disease (excluding intracranial disease) and the progression was determined based on either new extracranial lesions or progression of existing extracranial lesions.

    Time frame: Randomization to objective extracranial progression or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, up to 33 months)

  10. Time to Deterioration (TTD) in Participant Reported Pain, Dyspnea, or Cough Assessed Using Quality of Life Questionnaire Supplement Module for Lung Cancer (QLQ-LC13)

    The QLQ-LC13 consisted of 1 multi-item scale and 9 single items that assessed the specific symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer participants receiving chemotherapy. The QLQ-LC13 Coughing, Dyspnoea and Pain in chest each ranged from 0-100 with higher scores indicating a high level of symptomatology/problems. TTD in pain in chest, dyspnea, or cough from the QLQ-LC13 was a composite endpoint defined as the time from randomization to the earliest time the participant's scale scores showed a 10 point or greater increase after baseline in any of the 3 symptoms.

    Time frame: From Baseline to deterioration while on study treatment. For participants with no deterioration, the data was censored at the last date when QLQ-LC13 assessment for pain, dyspnea, or cough was completed (assessed up to 33 months)

  11. Change From Baseline in Functioning and Global Quality of Life (QOL) as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)

    EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). The QLQ-C30 Global QOL, Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, and Social Functioning each ranged from 0-100 with higher scores indicating a better level of functioning or better quality of life.

    Time frame: From Baseline to deterioration while on study treatment. For participants with no deterioration, the data was censored at the last date when QLQ-LC13 assessment for pain, dyspnea, or cough was completed (assessed up to 33 months)

  12. Change From Baseline Scores in QLQ-C30 Symptoms as Assessed by the EORTC-QLQ-C30

    EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). The QLQ-C30 Appetite loss, Constipation, Diarrhea, Dyspnea, Fatigue, Financial difficulties, Insomnia, Nausea/vomiting, and Pain each ranged from 0-100 with higher scores indicating a high level of symptomatology/problems.

    Time frame: From Baseline to deterioration while on study treatment. For participants with no deterioration, the data was censored at the last date when QLQ-LC13 assessment for pain, dyspnea, or cough was completed (assessed up to 33 months)

  13. Change From Baseline in Lung Cancer Symptom Scores as Assessed by the EORTC Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13)

    The QLQ-LC13 consisted of 1 multi-item scale and 9 single items that assessed the specific symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer participants receiving chemotherapy. The QLQ-LC13 Alopecia, Coughing, Dysphagia, Dyspnoea, Haemoptysis, Pain in arm or shoulder, Pain in chest, Pain in other parts, Peripheral neuropathy, and Sore mouth each ranged from 0-100 with higher scores indicating a high level of symptomatology/problems.

    Time frame: From Baseline to deterioration while on study treatment. For participants with no deterioration, the data was censored at the last date when QLQ-LC13 assessment for pain, dyspnea, or cough was completed (assessed up to 33 months)

  14. Change From Baseline in General Health Status as Assessed by EuroQol 5D (EQ-5D)-Visual Analog Scale (VAS)

    EQ-5D is a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a visual analog scale (VAS). The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.

    Time frame: From Baseline to deterioration while on study treatment. For participants with no deterioration, the data was censored at the last date when QLQ-LC13 assessment for pain, dyspnea, or cough was completed (assessed up to 33 months)

  15. Change From Baseline in General Health Status as Assessed by EQ-5D-Index

    EQ-5D is a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a visual analog scale (VAS). EQ-5D summary index is obtained with a formula that weights each level of the 5 dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health).

    Time frame: From Baseline to deterioration while on study treatment. For participants with no deterioration, the data was censored at the last date when QLQ-LC13 assessment for pain, dyspnea, or cough was completed (assessed up to 33 months)

  16. Percentage of Participants With Visual Disturbance as Assessed by Visual Symptom Assessment Questionnaire (VSAQ-ALK)

    VSAQ-ALK is a self-report measure that was developed to assess the problems of visual disturbances and symptoms may include the appearance of overlapping shadows and after images; shimmering, flashing or trailing lights; strings, streamers, or floaters; as well as hazy or blurry vision. The participants answered "Yes" to the first question (Q1) of VSAQ-ALK "Have you experienced any visual disturbances?" were considered to have experienced visual disturbance and were instructed to complete the rest of the questionnaire. The percentage of participants who responded to Q1 of VSAQ-ALK as "Yes" and as "No" during each study cycle was calculated as (n/N\*)\*100 where N\* was the number of participants who had completed Q1.

    Time frame: Cycle 1 Day 1 to end of treatment or withdrawal, no later than 4 weeks (+/- 1 week) from last dose of study medication or when the decision was taken to withdraw from the study (whichever was sooner, assessed up to Cycle 86)

  17. Agreement Between Central Laboratory ALK FISH and ALK IHC Test Results - Molecular Profiling Evaluable

    Agreement between central laboratory anaplastic lymphoma kinase (ALK) fluorescence in situ hybridization (FISH) and ALK immunohistochemistry (IHC) test results is based on analysis of participants in the Molecular Profiling (MP) evaluable population that have an ALK IHC result and an ALK FISH result of either positive or negative only. This MP evaluable population included participants who screen failed, which their ALK test results were negative based on FISH test. Tumor tissue samples from these screen failure participants were consented and kept. These samples served as a part of negative sample set for evaluation of IHC test and/or polymerase chain reaction (PCR) to determine ALK fusion events. Participants with FISH results of uninformative and assay not performed and IHC results of valid IHC status not available were excluded from the analysis of agreement between central laboratory ALK FISH and ALK IHC test results.

    Time frame: During the screening (less than or equal to 28 days prior to dosing)

  18. Percentage of Participants With Treatment-Emergent Adverse Events (AEs; All Causalities)

    An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. Grade 3 and 4 AEs in below table indicated severe AE and life-threatening consequences respectively; Grade 5 indicated death due to AE.

    Time frame: From the first dose of study medication up to 28 days after the last dose of study medication or up to the time that a participant died or received subsequent anticancer treatment (maximum duration between first and last dose: 324.4 weeks)

  19. Percentage of Participants With Treatment-Emergent AEs (Treatment Related)

    An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. Grade 3 and 4 AEs in below table indicated severe AE and life-threatening consequences respectively; Grade 5 indicated death due to AE.

    Time frame: From the first dose of study medication up to 28 days after the last dose of study medication or up to the time that a participant died or received subsequent anticancer treatment (maximum duration between first and last dose: 324.4 weeks)

07

Results

Posted Mar 13, 2017

Participant flow

This phase 3, randomized, open label, multicenter study conducted in 35 centers in 5 countries. A total of 207 actual participants were randomized, 104 in the crizotinib arm and 103 in the chemotherapy (pemetrexed/cisplatin or pemetrexed/carboplatin) arm.

Participant flow — Overall Study
MilestoneCrizotinibChemotherapy
Started104103
Treated104101
Completed2926
Not completed7577
Withdrew: Refused further follow-up912
Withdrew: Lost to follow-up30
Withdrew: Death6261
Withdrew: Randomized but not treated02
Withdrew: Long-term follow-up participants who did not respond to the contact from their study sites.12

Outcome measures

PrimaryProgression-Free Survival (PFS) Based on IRR by Treatment Arm

PFS was defined as the time from the date of randomization to the date of the first documentation of objective tumor progression (by IRR) or death on study due to any cause, whichever occured first. If tumor progression data included more than 1 date, the first date was used. PFS (in months) was calculated as (first event date - randomization date +1)/30.44. Progression is defined using RECIST v1.1, as at least a 20% increase (including an absolute increase of at least 5 millimeters) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

Time frame:
Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)
Reported as:
Median · Months
Progression-Free Survival (PFS) Based on IRR by Treatment Arm
MonthsCrizotinibChemotherapy
Progression-Free Survival (PFS) Based on IRR by Treatment Arm11.1 (8.3 to 12.6)6.8 (5.7 to 7.0)
Statistical analysis
  • Crizotinib vs Chemotherapy · 1 sided stratified log-rank · p = <0.0001 (The study was to be considered positive if the 1-sided log-rank test for PFS, stratified for baseline stratification factors (ECOG PS, ethnicity, and brain metastases) was significant at the 0.02496level.) · Hazard ratio (hr): 0.402 · 95% CI 0.286 to 0.565Based on the Cox Proportional hazards model stratified by ECOG PS, ethnicity, and brain metastases. Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of crizotinib.
SecondaryObjective Response Rate (ORR) - Percentage of Participants With Objective Response Based on IRR

Percentage of participants with objective response of complete response (CR) or partial response (PR) according to RECIST version 1.1. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

Time frame:
Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (assessed up to 33 months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) - Percentage of Participants With Objective Response Based on IRR
Percentage of participantsCrizotinibChemotherapy
Objective Response Rate (ORR) - Percentage of Participants With Objective Response Based on IRR87.5 (79.6 to 93.2)45.6 (35.8 to 55.7)
Statistical analysis
  • Crizotinib vs Chemotherapy · 2-sided pearson chi-square test · p = <0.0001 (If the PFS endpoint was significant, ORR was to be considered significant if 2-sided p-value from Pearson chi-square test was \<= 0.04992.) · Treatment difference: 41.869 · 95% CI 30.340 to 53.398Treatment difference in ORR (%)
SecondaryOverall Survival (OS)

OS was defined as the time from randomization to the date of death due to any cause. OS (in months) was calculated as (date of death - date of randomization +1)/30.44. For participants who were lost to follow-up or withdrew consent, the OS was censored on the last date that participants were known to be alive.

Time frame:
From randomization to death or last date known as alive for those who were lost to follow-up or withdrew consent (assessed up to 64 months).
Reported as:
Median · Months
Overall Survival (OS)
MonthsCrizotinibChemotherapy
Overall Survival (OS)33.7 (26.5 to 42.5)32.9 (23.9 to 43.1)
Statistical analysis
  • Crizotinib vs Chemotherapy · 1 sided stratified log-rank · p = 0.6172 (If the PFS and ORR endpoints were significant, OS was to be considered significant if 1-sided, log-rank test stratified for ECOG, ethnicity and metastases was \<= 0.02496.) · Hazard ratio (hr): 1.056 · 95% CI 0.734 to 1.521Based on the Cox Proportional hazards model stratified by ECOG PS, ethnicity, and brain metastases. Assuming proportional hazards, a hazard ratio less than 1 indicates a reduction in hazard rate in favor of crizotinib.
SecondaryPercentage of Participants With Disease Control at 12 Weeks Based on IRR

Disease Control Rate (DCR) at 12 weeks is defined as the percent of participants with CR, PR or stable disease (SD) at 12 weeks according to RECIST version 1.1 as determined by the IRR. The best response of SD can be assigned if SD criteria were met at least once after randomization at a minimum interval of 6 weeks. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions and disappearance of all non-target lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

Time frame:
From randomization to Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Disease Control at 12 Weeks Based on IRR
Percentage of participantsCrizotinibChemotherapy
Percentage of Participants With Disease Control at 12 Weeks Based on IRR82.7 (74.0 to 89.4)73.8 (64.2 to 82.0)
Statistical analysis
  • Crizotinib vs Chemotherapy · 2-sided pearson chi-square test · p = 0.1204 · Treatment difference: 8.906 · 95% CI -2.275 to 20.086Treatment Difference in DCR Rate (%)
SecondaryEstimate of the Percentage of Participants Surviving at 1 Year and at 18 Months

Probability of survival 1 year and 18 month after randomization. The probability of survival at 1 year was estimated using the Kaplan Meier method and a 2-sided 95% CI for the log \[-log(1-year survival probability)\] was calculated using a normal approximation and then back transformed to give a CI for the 1-year survival probability itself. The probability of survival at 18 months was estimated similarly.

Time frame:
From randomization to 1 year and from randomization to 18 months
Reported as:
Number · Percentage of paricipants
Estimate of the Percentage of Participants Surviving at 1 Year and at 18 Months
Percentage of paricipantsCrizotinibChemotherapy
Up to 1 year79.3 (70.0 to 86.0)79.5 (70.0 to 86.3)
Up to 18 months71.2 (61.2 to 79.0)72.1 (62.0 to 79.9)
SecondaryDuration of Response (DR) Based on IRR

DR was defined as the time from the first documentation of objective tumor response (CR or PR), as determined by the IRR, to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used. DR (in weeks) was calculated as (first date of PD or death - first date of CR or PR +1)/7. DR was only calculated for the subgroup of participants with an objective tumor response.

Time frame:
From objective response to date of progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, up to 33 months)
Reported as:
Median · Weeks
Duration of Response (DR) Based on IRR
WeeksCrizotinibChemotherapy
Duration of Response (DR) Based on IRR44.4 (35.9 to 60.0)18.1 (16.7 to 19.9)
SecondaryTime to Tumor Response (TTR) Based on IRR

TTR was defined as the time from randomization to first documentation of objective tumor response (CR or PR) as determined by the IRR. For participants proceeding from PR to CR, the onset of PR was taken as the onset of response. TTR was calculated for the subgroup of participants with objective tumor response.

Time frame:
Randomization to first documentation of objective tumor response (up to 33 months).
Reported as:
Median · Weeks
Time to Tumor Response (TTR) Based on IRR
WeeksCrizotinibChemotherapy
Time to Tumor Response (TTR) Based on IRR6.3 (5.1 to 24.9)12.1 (5.7 to 36.1)
SecondaryTime to Progression (TTP) Based on IRR

TTP was defined as the time from the date of randomization to the date of the first documentation of objective tumor progression, as determined by IRR. If tumor progression data included more than 1 date, the first date was used. TTP (in months) was calculated as (first event date - randomization date +1)/30.44.

Time frame:
Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, up to 33 months)
Reported as:
Median · Months
Time to Progression (TTP) Based on IRR
MonthsCrizotinibChemotherapy
Time to Progression (TTP) Based on IRR12.0 (8.4 to 15.4)6.9 (5.7 to 7.1)
Statistical analysis
  • Crizotinib vs Chemotherapy · 1 sided unstratified log-rank · p = <0.0001 · Hazard ratio (hr): 0.348 · 95% CI 0.246 to 0.493Based on the Cox Proportional hazards model.
SecondaryIntracranial Time to Progression (IC-TTP) Based on IRR

IC-TTP was defined similarly to TTP, but only considering intracranial disease (excluding extracranial disease) and the progression was determined based on either new brain metastases or progression of existing brain metastases.

Time frame:
Randomization to objective intracranial progression or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, up to 33 months)
Reported as:
Median · Months
Intracranial Time to Progression (IC-TTP) Based on IRR
MonthsCrizotinibChemotherapy
Intracranial Time to Progression (IC-TTP) Based on IRRNA (20.8 to NA)16.0 (12.6 to NA)
Statistical analysis
  • Crizotinib vs Chemotherapy · 1 sided unstratified log-rank · p = 0.1270 · Hazard ratio (hr): 0.669 · 95% CI 0.335 to 1.338Based on the Cox Proportional hazards model.
SecondaryExtracranial Time to Progression (EC-TTP) Based on IRR

EC-TTP was defined similarly to TTP, but only considering extracranial disease (excluding intracranial disease) and the progression was determined based on either new extracranial lesions or progression of existing extracranial lesions.

Time frame:
Randomization to objective extracranial progression or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, up to 33 months)
Reported as:
Median · Months
Extracranial Time to Progression (EC-TTP) Based on IRR
MonthsCrizotinibChemotherapy
Extracranial Time to Progression (EC-TTP) Based on IRR18.0 (12.3 to 20.9)7.0 (6.0 to 7.1)
Statistical analysis
  • Crizotinib vs Chemotherapy · 1 sided unstratified log-rank · p = <0.0001 · Hazard ratio (hr): 0.277 · 95% CI 0.186 to 0.412Based on the Cox Proportional hazards model.
SecondaryTime to Deterioration (TTD) in Participant Reported Pain, Dyspnea, or Cough Assessed Using Quality of Life Questionnaire Supplement Module for Lung Cancer (QLQ-LC13)

The QLQ-LC13 consisted of 1 multi-item scale and 9 single items that assessed the specific symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer participants receiving chemotherapy. The QLQ-LC13 Coughing, Dyspnoea and Pain in chest each ranged from 0-100 with higher scores indicating a high level of symptomatology/problems. TTD in pain in chest, dyspnea, or cough from the QLQ-LC13 was a composite endpoint defined as the time from randomization to the earliest time the participant's scale scores showed a 10 point or greater increase after baseline in any of the 3 symptoms.

Time frame:
From Baseline to deterioration while on study treatment. For participants with no deterioration, the data was censored at the last date when QLQ-LC13 assessment for pain, dyspnea, or cough was completed (assessed up to 33 months)
Reported as:
Median · Months
Time to Deterioration (TTD) in Participant Reported Pain, Dyspnea, or Cough Assessed Using Quality of Life Questionnaire Supplement Module for Lung Cancer (QLQ-LC13)
MonthsCrizotinibChemotherapy
Time to Deterioration (TTD) in Participant Reported Pain, Dyspnea, or Cough Assessed Using Quality of Life Questionnaire Supplement Module for Lung Cancer (QLQ-LC13)2.8 (1.4 to 6.9)0.3 (0.3 to 0.5)
Statistical analysis
  • Crizotinib vs Chemotherapy · 2 sided unstratified log rank · p = <0.0001 (2-sided Hochberg adjusted p-values) · Hazard ratio (hr): 0.432 · 95% CI 0.307 to 0.610Based on the Cox Proportional hazards model.
SecondaryChange From Baseline in Functioning and Global Quality of Life (QOL) as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)

EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). The QLQ-C30 Global QOL, Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, and Social Functioning each ranged from 0-100 with higher scores indicating a better level of functioning or better quality of life.

Time frame:
From Baseline to deterioration while on study treatment. For participants with no deterioration, the data was censored at the last date when QLQ-LC13 assessment for pain, dyspnea, or cough was completed (assessed up to 33 months)
Reported as:
Mean · Units on a scale
Change From Baseline in Functioning and Global Quality of Life (QOL) as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)
Units on a scaleCrizotinibChemotherapy
QLQ-C30 Global QoL5.0891 (2.53 to 7.64)-2.3619 (-5.00 to 0.28)
QLQ-C30 Cognitive Functioning-1.1896 (-3.28 to 0.90)-4.8026 (-6.95 to -2.66)
QLQ-C30 Emotional Functioning3.7077 (1.76 to 5.66)2.0557 (0.04 to 4.07)
QLQ-C30 Physical Functioning3.7705 (1.97 to 5.57)-2.9562 (-4.82 to -1.10)
QLQ-C30 Role Functioning1.0538 (-1.56 to 3.66)-5.7570 (-8.44 to -3.07)
QLQ-C30 Social Functioning0.8712 (-2.27 to 4.02)-4.7228 (-7.96 to -1.49)
Statistical analysis
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = <0.0001 · Mean difference (net): 7.4510 · 95% CI 3.79 to 11.11
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = 0.0140 · Mean difference (net): 3.6130 · 95% CI 0.73 to 6.49
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = 0.2427 · Mean difference (net): 1.6520 · 95% CI -1.12 to 4.42
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = <0.0001 · Mean difference (net): 6.7267 · 95% CI 4.15 to 9.30
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = 0.0003 · Mean difference (net): 6.8109 · 95% CI 3.15 to 10.47
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = 0.0140 · Mean difference (net): 5.5940 · 95% CI 1.13 to 10.06
SecondaryChange From Baseline Scores in QLQ-C30 Symptoms as Assessed by the EORTC-QLQ-C30

EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). The QLQ-C30 Appetite loss, Constipation, Diarrhea, Dyspnea, Fatigue, Financial difficulties, Insomnia, Nausea/vomiting, and Pain each ranged from 0-100 with higher scores indicating a high level of symptomatology/problems.

Time frame:
From Baseline to deterioration while on study treatment. For participants with no deterioration, the data was censored at the last date when QLQ-LC13 assessment for pain, dyspnea, or cough was completed (assessed up to 33 months)
Reported as:
Mean · Units on a scale
Change From Baseline Scores in QLQ-C30 Symptoms as Assessed by the EORTC-QLQ-C30
Units on a scaleCrizotinibChemotherapy
QLQ-C30 Appetite loss-1.5967 (-4.18 to 0.99)4.4465 (1.74 to 7.15)
QLQ-C30 Constipation7.1367 (4.40 to 9.87)2.6341 (-0.23 to 5.50)
QLQ-C30 Diarrhea15.3294 (13.35 to 17.31)-0.4791 (-2.55 to 1.60)
QLQ-C30 Dyspnea-7.9353 (-10.41 to -5.46)-0.1903 (-2.75 to 2.37)
QLQ-C30 Fatigue-3.8888 (-6.20 to -1.58)2.6028 (0.21 to 5.00)
QLQ-C30 Financial Difficulties-3.2339 (-7.26 to 0.79)0.3826 (-3.74 to 4.51)
QLQ-C30 Insomnia-8.3816 (-10.95 to -5.81)-1.6060 (-4.29 to 1.07)
QLQ-C30 Nausea and Vomiting4.0796 (2.06 to 6.09)6.5986 (4.48 to 8.72)
QLQ-C30 Pain-9.1305 (-11.27 to -6.99)-0.6956 (-2.90 to 1.51)
Statistical analysis
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = 0.0016 · Mean difference (net): -6.0432 · 95% CI -9.79 to -2.30
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = 0.0263 · Mean difference (net): 4.5026 · 95% CI 0.53 to 8.47
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = <0.0001 · Mean difference (net): 15.8085 · 95% CI 12.94 to 18.68
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = <0.0001 · Mean difference (net): -7.7449 · 95% CI -11.30 to -4.19
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = 0.0001 · Mean difference (net): -6.4915 · 95% CI -9.82 to -3.17
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = 0.2099 · Mean difference (net): -3.6165 · 95% CI -9.27 to 2.04
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = 0.0004 · Mean difference (net): -6.7756 · 95% CI -10.49 to -3.06
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = 0.0902 · Mean difference (net): -2.5190 · 95% CI -5.43 to 0.40
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = <0.0001 · Mean difference (net): -8.4349 · 95% CI -11.42 to -5.45
SecondaryChange From Baseline in Lung Cancer Symptom Scores as Assessed by the EORTC Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13)

The QLQ-LC13 consisted of 1 multi-item scale and 9 single items that assessed the specific symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer participants receiving chemotherapy. The QLQ-LC13 Alopecia, Coughing, Dysphagia, Dyspnoea, Haemoptysis, Pain in arm or shoulder, Pain in chest, Pain in other parts, Peripheral neuropathy, and Sore mouth each ranged from 0-100 with higher scores indicating a high level of symptomatology/problems.

Time frame:
From Baseline to deterioration while on study treatment. For participants with no deterioration, the data was censored at the last date when QLQ-LC13 assessment for pain, dyspnea, or cough was completed (assessed up to 33 months)
Reported as:
Mean · Units on a scale
Change From Baseline in Lung Cancer Symptom Scores as Assessed by the EORTC Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13)
Units on a scaleCrizotinibChemotherapy
QLQ-LC13 Alopecia-2.0837 (-4.41 to 0.24)2.7710 (0.37 to 5.18)
QLQ-LC13 Coughing-17.2704 (-19.96 to -14.58)-10.2748 (-13.07 to -7.48)
QLQ-LC13 Dysphagia0.5354 (-1.34 to 2.41)1.0535 (-0.90 to 3.01)
QLQ-LC13 Dyspnoea-9.0842 (-11.34 to -6.83)-0.4371 (-2.76 to 1.89)
QLQ-LC13 Haemoptysis-4.3017 (-5.42 to -3.18)-3.0513 (-4.22 to -1.88)
QLQ-LC13 Pain in Arm or Shoulder-6.8289 (-9.43 to -4.23)-2.5927 (-5.29 to 0.11)
QLQ-LC13 Pain in Chest-8.3565 (-10.81 to -5.90)-4.1328 (-6.68 to -1.58)
QLQ-LC13 Pain in Other Parts-4.8475 (-7.22 to -2.48)-0.2573 (-2.72 to 2.21)
QLQ-LC13 Peripheral Neuropathy0.1787 (-1.94 to 2.30)1.8519 (-0.36 to 4.06)
QLQ-LC13 Sore Mouth1.5134 (-0.01 to 3.03)3.9114 (2.30 to 5.53)
Statistical analysis
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = 0.0039 · Mean difference (net): -4.8547 · 95% CI -8.15 to -1.56
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = 0.0004 · Mean difference (net): -6.9957 · 95% CI -10.85 to -3.14
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = 0.7082 · Mean difference (net): -0.5181 · 95% CI -3.23 to 2.20
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = <0.0001 · Mean difference (net): -8.6471 · 95% CI -11.85 to -5.44
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = 0.1284 · Mean difference (net): -1.2504 · 95% CI -2.86 to 0.36
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = 0.0265 · Mean difference (net): -4.2363 · 95% CI -7.98 to -0.49
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = 0.0185 · Mean difference (net): -4.2237 · 95% CI -7.74 to -0.71
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = 0.0075 · Mean difference (net): -4.5901 · 95% CI -7.95 to -1.23
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = 0.2848 · Mean difference (net): -1.6732 · 95% CI -4.74 to 1.39
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = 0.0296 · Mean difference (net): -2.3980 · 95% CI -4.56 to -0.24
SecondaryChange From Baseline in General Health Status as Assessed by EuroQol 5D (EQ-5D)-Visual Analog Scale (VAS)

EQ-5D is a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a visual analog scale (VAS). The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.

Time frame:
From Baseline to deterioration while on study treatment. For participants with no deterioration, the data was censored at the last date when QLQ-LC13 assessment for pain, dyspnea, or cough was completed (assessed up to 33 months)
Reported as:
Mean · Units on a scale
Change From Baseline in General Health Status as Assessed by EuroQol 5D (EQ-5D)-Visual Analog Scale (VAS)
Units on a scaleCrizotinibChemotherapy
Change From Baseline in General Health Status as Assessed by EuroQol 5D (EQ-5D)-Visual Analog Scale (VAS)3.4209 (1.20 to 5.64)-0.4927 (-2.75 to 1.77)
Statistical analysis
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = 0.0123 · Mean difference (net): 3.9136 · 95% CI 0.85 to 6.98
SecondaryChange From Baseline in General Health Status as Assessed by EQ-5D-Index

EQ-5D is a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a visual analog scale (VAS). EQ-5D summary index is obtained with a formula that weights each level of the 5 dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health).

Time frame:
From Baseline to deterioration while on study treatment. For participants with no deterioration, the data was censored at the last date when QLQ-LC13 assessment for pain, dyspnea, or cough was completed (assessed up to 33 months)
Reported as:
Mean · Units on a scale
Change From Baseline in General Health Status as Assessed by EQ-5D-Index
Units on a scaleCrizotinibChemotherapy
Change From Baseline in General Health Status as Assessed by EQ-5D-Index0.0502 (0.02 to 0.08)0.0077 (-0.02 to 0.04)
Statistical analysis
  • Crizotinib vs Chemotherapy · Mixed Models Analysis · p = 0.0320 · Mean difference (net): 0.0425 · 95% CI 0.00 to 0.08
SecondaryPercentage of Participants With Visual Disturbance as Assessed by Visual Symptom Assessment Questionnaire (VSAQ-ALK)

VSAQ-ALK is a self-report measure that was developed to assess the problems of visual disturbances and symptoms may include the appearance of overlapping shadows and after images; shimmering, flashing or trailing lights; strings, streamers, or floaters; as well as hazy or blurry vision. The participants answered "Yes" to the first question (Q1) of VSAQ-ALK "Have you experienced any visual disturbances?" were considered to have experienced visual disturbance and were instructed to complete the rest of the questionnaire. The percentage of participants who responded to Q1 of VSAQ-ALK as "Yes" and as "No" during each study cycle was calculated as (n/N\*)\*100 where N\* was the number of participants who had completed Q1.

Time frame:
Cycle 1 Day 1 to end of treatment or withdrawal, no later than 4 weeks (+/- 1 week) from last dose of study medication or when the decision was taken to withdraw from the study (whichever was sooner, assessed up to Cycle 86)
Reported as:
Number · Percentage of participants
Percentage of Participants With Visual Disturbance as Assessed by Visual Symptom Assessment Questionnaire (VSAQ-ALK)
Percentage of participantsCrizotinibChemotherapy
Baseline: Cycle 1/Day 1 (Answer to Q1: Yes)6.87.1
Baseline: Cycle 1/Day 1 (Answer to Q1: No)93.292.9
Cycle 2/Day 1 (Answer to Q1: Yes)51.013.4
Cycle 2/Day 1 (Answer to Q1: No)49.086.6
Cycle 3/Day 1 (Answer to Q1: Yes)46.111.1
Cycle 3/Day 1 (Answer to Q1: No)53.988.9
Cycle 4/Day 1 (Answer to Q1: Yes)43.914.8
Cycle 4/Day 1 (Answer to Q1: No)56.185.2
Cycle 5/Day 1 (Answer to Q1: Yes)35.813.5
Cycle 5/Day 1 (Answer to Q1: No)64.286.5
Cycle 6/Day 1 (Answer to Q1: Yes)37.410.1
Cycle 6/Day 1 (Answer to Q1: No)62.689.9
Cycle 7/Day 1 (Answer to Q1: Yes)36.0—
Cycle 7/Day 1 (Answer to Q1: No)64.0—
Cycle 8/Day 1 (Answer to Q1: Yes)28.1—
Cycle 8/Day 1 (Answer to Q1: No)71.9—
Cycle 9/Day 1 (Answer to Q1: Yes)24.1—
Cycle 9/Day 1 (Answer to Q1: No)75.9—
Cycle 10/Day 1 (Answer to Q1: Yes)23.9—
Cycle 10/Day 1 (Answer to Q1: No)76.1—
Cycle 11/Day 1 (Answer to Q1: Yes)23.5—
Cycle 11/Day 1 (Answer to Q1: No)76.5—
Cycle 12/Day 1 (Answer to Q1: Yes)21.3—
Cycle 12/Day 1 (Answer to Q1: No)78.8—
Cycle 13/Day 1 (Answer to Q1: Yes)25.3—
Cycle 13/Day 1 (Answer to Q1: No)74.7—
Cycle 14/Day 1 (Answer to Q1: Yes)27.0—
Cycle 14/Day 1 (Answer to Q1: No)73.0—
Cycle 15/Day 1 (Answer to Q1: Yes)28.2—
Cycle 15/Day 1 (Answer to Q1: No)71.8—
Cycle 16/Day 1 (Answer to Q1: Yes)28.6—
Cycle 16/Day 1 (Answer to Q1: No)71.4—
Cycle 17/Day 1 (Answer to Q1: Yes)28.6—
Cycle 17/Day 1 (Answer to Q1: No)71.4—
Cycle 18/Day 1 (Answer to Q1: Yes)28.4—
Cycle 18/Day 1 (Answer to Q1: No)71.6—
Cycle 19/Day 1 (Answer to Q1: Yes)28.1—
Cycle 19/Day 1 (Answer to Q1: No)71.9—
Cycle 20/Day 1 (Answer to Q1: Yes)27.9—
Cycle 20/Day 1 (Answer to Q1: No)72.1—
Cycle 21/Day 1 (Answer to Q1: Yes)30.5—
Cycle 21/Day 1 (Answer to Q1: No)69.5—
Cycle 22/Day 1 (Answer to Q1: Yes)29.1—
Cycle 22/Day 1 (Answer to Q1: No)70.9—
Cycle 23/Day 1 (Answer to Q1: Yes)28.6—
Cycle 23/Day 1 (Answer to Q1: No)71.4—
Cycle 24/Day 1 (Answer to Q1: Yes)31.5—
Cycle 24/Day 1 (Answer to Q1: No)68.5—
Cycle 25/Day 1 (Answer to Q1: Yes)32.1—
Cycle 25/Day 1 (Answer to Q1: No)67.9—
Cycle 26/Day 1 (Answer to Q1: Yes)28.8—
Cycle 26/Day 1 (Answer to Q1: No)71.2—
Cycle 27/Day 1 (Answer to Q1: Yes)28.0—
Cycle 27/Day 1 (Answer to Q1: No)72.0—
Cycle 28/Day 1 (Answer to Q1: Yes)30.0—
Cycle 28/Day 1 (Answer to Q1: No)70.0—
Cycle 29/Day 1 (Answer to Q1: Yes)30.0—
Cycle 29/Day 1 (Answer to Q1: No)70.0—
Cycle 30/Day 1 (Answer to Q1: Yes)32.0—
Cycle 30/Day 1 (Answer to Q1: No)68.0—
Cycle 31/Day 1 (Answer to Q1: Yes)24.5—
Cycle 31/Day 1 (Answer to Q1: No)75.5—
Cycle 32/Day 1 (Answer to Q1: Yes)25.0—
Cycle 32/Day 1 (Answer to Q1: No)75.0—
Cycle 33/Day 1 (Answer to Q1: Yes)28.3—
Cycle 33/Day 1 (Answer to Q1: No)71.7—
Cycle 34/Day 1 (Answer to Q1: Yes)27.3—
Cycle 34/Day 1 (Answer to Q1: No)72.7—
Cycle 35/Day 1 (Answer to Q1: Yes)28.6—
Cycle 35/Day 1 (Answer to Q1: No)71.4—
Cycle 36/Day 1 (Answer to Q1: Yes)26.8—
Cycle 36/Day 1 (Answer to Q1: No)73.2—
Cycle 37/Day 1 (Answer to Q1: Yes)27.0—
Cycle 37/Day 1 (Answer to Q1: No)73.0—
Cycle 38/Day 1 (Answer to Q1: Yes)24.3—
Cycle 38/Day 1 (Answer to Q1: No)75.7—
Cycle 39/Day 1 (Answer to Q1: Yes)30.3—
Cycle 39/Day 1 (Answer to Q1: No)69.7—
Cycle 40/Day 1 (Answer to Q1: Yes)25.0—
Cycle 40/Day 1 (Answer to Q1: No)75.0—
Cycle 41/Day 1 (Answer to Q1: Yes)32.3—
Cycle 41/Day 1 (Answer to Q1: No)67.7—
Cycle 42/Day 1 (Answer to Q1: Yes)25.8—
Cycle 42/Day 1 (Answer to Q1: No)74.2—
Cycle 43/Day 1 (Answer to Q1: Yes)24.1—
Cycle 43/Day 1 (Answer to Q1: No)75.9—
Cycle 44/Day 1 (Answer to Q1: Yes)30.0—
Cycle 44/Day 1 (Answer to Q1: No)70.0—
Cycle 45/Day 1 (Answer to Q1: Yes)25.0—
Cycle 45/Day 1 (Answer to Q1: No)75.0—
Cycle 46/Day 1 (Answer to Q1: Yes)27.6—
Cycle 46/Day 1 (Answer to Q1: No)72.4—
Cycle 47/Day 1 (Answer to Q1: Yes)26.9—
Cycle 47/Day 1 (Answer to Q1: No)73.1—
Cycle 48/Day 1 (Answer to Q1: Yes)29.6—
Cycle 48/Day 1 (Answer to Q1: No)70.4—
Cycle 49/Day 1 (Answer to Q1: Yes)29.2—
Cycle 49/Day 1 (Answer to Q1: No)70.8—
Cycle 50/Day 1 (Answer to Q1: Yes)29.2—
Cycle 50/Day 1 (Answer to Q1: No)70.8—
Cycle 51/Day 1 (Answer to Q1: Yes)26.1—
Cycle 51/Day 1 (Answer to Q1: No)73.9—
Cycle 52/Day 1 (Answer to Q1: Yes)29.2—
Cycle 52/Day 1 (Answer to Q1: No)70.8—
Cycle 53/Day 1 (Answer to Q1: Yes)25.0—
Cycle 53/Day 1 (Answer to Q1: No)75.0—
Cycle 54/Day 1 (Answer to Q1: Yes)36.4—
Cycle 54/Day 1 (Answer to Q1: No)63.6—
Cycle 55/Day 1 (Answer to Q1: Yes)29.4—
Cycle 55/Day 1 (Answer to Q1: No)70.6—
Cycle 56/Day 1 (Answer to Q1: Yes)38.9—
Cycle 56/Day 1 (Answer to Q1: No)61.1—
Cycle 57/Day 1 (Answer to Q1: Yes)20.0—
Cycle 57/Day 1 (Answer to Q1: No)80.0—
Cycle 58/Day 1 (Answer to Q1: Yes)35.3—
Cycle 58/Day 1 (Answer to Q1: No)64.7—
Cycle 59/Day 1 (Answer to Q1: Yes)21.4—
Cycle 59/Day 1 (Answer to Q1: No)78.6—
Cycle 60/Day 1 (Answer to Q1: Yes)37.5—
Cycle 60/Day 1 (Answer to Q1: No)62.5—
Cycle 61/Day 1 (Answer to Q1: Yes)23.1—
Cycle 61/Day 1 (Answer to Q1: No)76.9—
Cycle 62/Day 1 (Answer to Q1: Yes)37.5—
Cycle 62/Day 1 (Answer to Q1: No)62.5—
Cycle 63/Day 1 (Answer to Q1: Yes)21.4—
Cycle 63/Day 1 (Answer to Q1: No)78.6—
Cycle 64/Day 1 (Answer to Q1: Yes)35.7—
Cycle 64/Day 1 (Answer to Q1: No)64.3—
Cycle 65/Day 1 (Answer to Q1: Yes)21.4—
Cycle 65/Day 1 (Answer to Q1: No)78.6—
Cycle 66/Day 1 (Answer to Q1: Yes)30.8—
Cycle 66/Day 1 (Answer to Q1: No)69.2—
Cycle 67/Day 1 (Answer to Q1: Yes)25.0—
Cycle 67/Day 1 (Answer to Q1: No)75.0—
Cycle 68/Day 1 (Answer to Q1: Yes)30.8—
Cycle 68/Day 1 (Answer to Q1: No)69.2—
Cycle 69/Day 1 (Answer to Q1: Yes)25.0—
Cycle 69/Day 1 (Answer to Q1: No)75.0—
Cycle 70/Day 1 (Answer to Q1: Yes)30.8—
Cycle 70/Day 1 (Answer to Q1: No)69.2—
Cycle 71/Day 1 (Answer to Q1: Yes)30.0—
Cycle 71/Day 1 (Answer to Q1: No)70.0—
Cycle 72/Day 1 (Answer to Q1: Yes)22.2—
Cycle 72/Day 1 (Answer to Q1: No)77.8—
Cycle 73/Day 1 (Answer to Q1: Yes)22.2—
Cycle 73/Day 1 (No)77.8—
Cycle 74/Day 1 (Answer to Q1: Yes)25.0—
Cycle 74/Day 1 (Answer to Q1: No)75.0—
Cycle 75/Day 1 (Answer to Q1: Yes)22.2—
Cycle 75/Day 1 (Answer to Q1: No)77.8—
Cycle 76/Day 1 (Answer to Q1: Yes)16.7—
Cycle 76/Day 1 (Answer to Q1: No)83.3—
Cycle 77/Day 1 (Answer to Q1: Yes)37.5—
Cycle 77/Day 1 (Answer to Q1: No)62.5—
Cycle 78/Day 1 (Answer to Q1: Yes)20.0—
Cycle 78/Day 1 (Answer to Q1: No)80.0—
Cycle 79/Day 1 (Answer to Q1: Yes)20.0—
Cycle 79/Day 1 (Answer to Q1: No)80.0—
Cycle 80/Day 1 (Answer to Q1: Yes)0.0—
Cycle 80/Day 1 (Answer to Q1: No)100.0—
Cycle 81/Day 1 (Answer to Q1: Yes)0.0—
Cycle 81/Day 1 (Answer to Q1: No)100.0—
Cycle 82/Day 1 (Answer to Q1: Yes)0.0—
Cycle 82/Day 1 Answer to Q1: (No)100.0—
Cycle 83/Day 1 (Answer to Q1: Yes)0.0—
Cycle 83/Day 1 (Answer to Q1: No)100.0—
Cycle 84/Day 1 (Answer to Q1: Yes)0.0—
Cycle 84/Day 1 (Answer to Q1: No)100.0—
Cycle 86/Day 1 (Answer to Q1: Yes)0.0—
Cycle 86/Day 1 (Answer to Q1: No)100.0—
SecondaryAgreement Between Central Laboratory ALK FISH and ALK IHC Test Results - Molecular Profiling Evaluable

Agreement between central laboratory anaplastic lymphoma kinase (ALK) fluorescence in situ hybridization (FISH) and ALK immunohistochemistry (IHC) test results is based on analysis of participants in the Molecular Profiling (MP) evaluable population that have an ALK IHC result and an ALK FISH result of either positive or negative only. This MP evaluable population included participants who screen failed, which their ALK test results were negative based on FISH test. Tumor tissue samples from these screen failure participants were consented and kept. These samples served as a part of negative sample set for evaluation of IHC test and/or polymerase chain reaction (PCR) to determine ALK fusion events. Participants with FISH results of uninformative and assay not performed and IHC results of valid IHC status not available were excluded from the analysis of agreement between central laboratory ALK FISH and ALK IHC test results.

Time frame:
During the screening (less than or equal to 28 days prior to dosing)
Reported as:
Count of participants · Participants
Agreement Between Central Laboratory ALK FISH and ALK IHC Test Results - Molecular Profiling Evaluable
ParticipantsParticipants With Positive ALK FISH StatusParticipants With Negative ALK FISH Status
Participants with Positive ALK IHC Status218 (91.4 to 94.9)31
Participants with Negative ALK IHC Status20502
Statistical analysis
  • Participants With Positive ALK FISH Status vs Participants With Negative ALK FISH Status · Overall percent agreement: 0.934 · 95% CI 0.914 to 0.94995% CI for agreement rate is calculated by the Wilson (Score) Confidence Limit method with alpha=0.05
  • Participants With Positive ALK FISH Status vs Participants With Negative ALK FISH Status · Kappa: 0.8470 · 95% CI 0.8065 to 0.8875Kappa coefficient is a statistic which measures inter-rater agreement for qualitative (categorical) items.
SecondaryPercentage of Participants With Treatment-Emergent Adverse Events (AEs; All Causalities)

An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. Grade 3 and 4 AEs in below table indicated severe AE and life-threatening consequences respectively; Grade 5 indicated death due to AE.

Time frame:
From the first dose of study medication up to 28 days after the last dose of study medication or up to the time that a participant died or received subsequent anticancer treatment (maximum duration between first and last dose: 324.4 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (AEs; All Causalities)
Percentage of participantsCrizotinibChemotherapy
AEs99.099.0
SAEs44.212.9
Grade 3/4 AEs58.752.5
Grade 5 AEs22.12.0
AEs associated with permanent discontinuation26.94.0
AEs associated with dose reduction14.47.9
AEs associated with temporary discontinuation39.437.6
SecondaryPercentage of Participants With Treatment-Emergent AEs (Treatment Related)

An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death, initial or prolonged inpatient hospitalization, life-threatening experience, persistent or significant disability/incapacity, congenital anomaly. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. Grade 3 and 4 AEs in below table indicated severe AE and life-threatening consequences respectively; Grade 5 indicated death due to AE.

Time frame:
From the first dose of study medication up to 28 days after the last dose of study medication or up to the time that a participant died or received subsequent anticancer treatment (maximum duration between first and last dose: 324.4 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment-Emergent AEs (Treatment Related)
Percentage of participantsCrizotinibChemotherapy
AEs98.196.0
Serious AEs8.73.0
Grade 3/4 AEs43.340.6
Grade 5 AEs1.90
AEs associated with permanent discontinuation5.81.0
AEs associated with dose reduction13.57.9
AEs associated with temporary discontinuation28.831.7

Adverse events

Collected over From the first dose of study medication up to 28 days after the last dose of study medication or up to the time that a participant died or received subsequent anticancer treatment (maximum duration between first and last dose: 324.4 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Crizotinib62/104 (59.6%)46/104 (44.2%)103/104 (99%)
Chemotherapy61/101 (60.4%)13/101 (12.9%)100/101 (99%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventCrizotinibChemotherapy
Disease progressionGeneral disorders15/1041/101
PneumoniaInfections and infestations5/1041/101
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/1040/101
ThrombocytopeniaBlood and lymphatic system disorders0/1042/101
HaemoptysisRespiratory, thoracic and mediastinal disorders1/1042/101
DysphagiaGastrointestinal disorders2/1040/101
DeathGeneral disorders2/1041/101
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders2/1040/101
Pleural effusionRespiratory, thoracic and mediastinal disorders2/1041/101
PneumothoraxRespiratory, thoracic and mediastinal disorders2/1040/101
Most frequent other events
Showing 10 of 72
Most frequent other events
EventCrizotinibChemotherapy
Alanine aminotransferase increasedInvestigations69/10445/101
DiarrhoeaGastrointestinal disorders63/1049/101
Aspartate aminotransferase increasedInvestigations62/10435/101
VomitingGastrointestinal disorders61/10446/101
White blood cell count decreasedInvestigations43/10456/101
NauseaGastrointestinal disorders56/10450/101
AnaemiaBlood and lymphatic system disorders20/10449/101
Visual impairmentEye disorders42/1048/101
Neutrophil count decreasedInvestigations40/10433/101
NeutropeniaBlood and lymphatic system disorders21/10437/101

Baseline characteristics

Age, Continuous
Age, Continuous(Years)CrizotinibChemotherapyTotal
Mean48.2 ± 10.648.9 ± 11.248.5 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)CrizotinibChemotherapyTotal
Female5460114
Male504393
08

Study locations

47 sites
  • The First Affiliated Hospital of Anhui Medical University, Department of Medical Oncology
    Hefei, Anhui 230002, China
  • Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
  • Dept. of Respiration. Peking Union Medical College Hospital
    Beijing, Beijing 100032, China
  • Peking Union Medical College Hospital
    Beijing, Beijing 100032, China
  • Chinese PLA General Hospital
    Beijing, Beijing 100853, China
  • Beijing Chest Hospital, Capital Medical University
    Beijing, Beijing 101149, China
  • Oncology Department, the Second Affiliated Hospital of Third Military Medical University,PLA
    Chongqing, Chongqing 400037, China
  • Oncology Department, XinQiao Hospital of Third Military Medical University,
    Chongqing, Chongqing 400037, China
  • Fujian Province Oncology Hospital
    Fuzhou, Fujian 350014, China
  • SUN Yat-Sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Guangdong General Hospital, Oncology Center
    Guangzhou, Guangdong 510080, China
  • The First Affiliated Hospital of Guangzhou Medical College/Thoracic Surgery
    Guangzhou, Guangdong 510120, China
  • Department 2 of Chemotherapy, Tumour Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi 530021, China
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology/Cancer Center
    Wuhan, Hubei 430030, China
  • Hunan Provincial Tumor Hospital/Division of Oncology
    Changsha, Hunan 410013, China
  • Nanjing General Hospital of Nanjing Military Command, Department of Respiratory medicine
    Nanjing, Jiangsu 210002, China
  • Department of Oncology, Jilin Provincial Cancer Hospital
    Changchun, Jilin 130012, China
  • The first hospital of China Medical University/Oncology Department
    Shenyang, Liaoning 110001, China
  • Oncology Department, West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • Sichuan Province Cancer Hospital/Department of Pulmonary Tumor
    Chengdu, Sichuan 610041, China
  • Department of Respiratory, The First Affiliated Hospital of College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310003, China
  • Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology
    Hangzhou, Zhejiang 310016, China
  • 307 Hospital of PLA/Department of Lung Cancer
    Beijing, 100071, China
  • Beijing Cancer Hospital
    Beijing, 100142, China
  • The Military General Hospital of Beijing PLA
    Beijing, 100700, China
  • Peking Union Medical College Hospital
    Beijing, 100730, China
  • Chinese PLA General Hospital
    Beijing, 100853, China
  • Beijing Chest Hospital, Capital Medical University
    Beijing, 101149, China
  • Respiration department,the First Affiliated Hospital of Third Military Medical University, PLA
    Chongqing, 400038, China
  • Shanghai Chest Hospital/Lung cancer clinical center
    Shanghai, 200030, China
  • Shanghai Chest Hospital
    Shanghai, 200030, China
  • Zhongshan Hospital Fudan University / Respiratory Department
    Shanghai, 200032, China
  • Shanghai First People's Hospital
    Shanghai, 200080, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, 300060, China
  • Pamela Youde Nethersole Eastern Hospital
    Chai Wan, 0, Hong Kong
  • Queen Mary Hospital
    Hong Kong, 0, Hong Kong
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • Prince of Wales Hospital
    Shatin, Hong Kong
  • Department of Nuclear Medicine, Radiotherapy and Oncology, Hospital Universiti Sains Malaysia
    Kubang Kerian, Kota Bahru, Kelantan 16150, Malaysia
  • Hospital Pulau Pinang
    Georgetown, Pulau Pinang 10990, Malaysia
  • Chi Mei Medical Center Liouying
    Liou Ying Township, Tainan 736, Taiwan
  • Chung Shan Medical University Hospital
    Taichung, 402, Taiwan
  • Chi Mei Medical Center Liuying
    Tainan city, 736, Taiwan
  • Taipei Veterans General Hospital, Chest Department
    Taipei, 11217, Taiwan
  • Chang Gung Medical Foundation, LinKou Branch
    Taoyuan, 333, Taiwan
  • Medical Oncology Unit, Department of Medicine, Faculty of Medicine, Chulalongkorn University
    Pathumwan, Bangkok 10330, Thailand
  • Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Siriraj Hospital,
    Bangkok, 10700, Thailand
09

References and documents

Publications

  • Wu YL, Lu S, Lu Y, Zhou J, Shi YK, Sriuranpong V, Ho JCM, Ong CK, Tsai CM, Chung CH, Wilner KD, Tang Y, Masters ET, Selaru P, Mok TS. Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 Oct;13(10):1539-1548. doi: 10.1016/j.jtho.2018.06.012. Epub 2018 Aug 14. PubMed 29966800 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2012 to primary completion in Jun 2015, 33 months.

Results were first posted in Mar 2017, 1 year 8 months after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 33 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2012
First posted
Jul 12, 2012
StartActual
Sep 29, 2012
Primary completionActual
Jun 30, 2015
CompletionActual
Jan 8, 2020
Results first posted
Mar 13, 2017
Last update
Dec 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01639001
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 12, 2012
Start date
Sep 29, 2012
Primary completion
Jun 30, 2015
Completion
Jan 8, 2020
Results posted
Mar 13, 2017
Last update
Dec 8, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crizotinib

Start the discussion